Repligen Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Olivier Loeillot

Geschäftsführender

US$5.4m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts2.5%
Amtszeit als Geschäftsführer1.1yrs
Eigentum des Geschäftsführersn/a
Durchschnittliche Amtszeit des Managements1.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder8.7yrs

Jüngste Management Updates

Recent updates

Repligen Corporation's Earnings Preview: Expensive With Mixed Growth Prospects

Nov 12

Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

Nov 08
Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

Is It Time To Consider Buying Repligen Corporation (NASDAQ:RGEN)?

Oct 14
Is It Time To Consider Buying Repligen Corporation (NASDAQ:RGEN)?

Repligen Corporation's (NASDAQ:RGEN) Intrinsic Value Is Potentially 28% Above Its Share Price

Sep 08
Repligen Corporation's (NASDAQ:RGEN) Intrinsic Value Is Potentially 28% Above Its Share Price

Repligen Corporation (NASDAQ:RGEN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

Jul 31
Repligen Corporation (NASDAQ:RGEN) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable

We Think Repligen (NASDAQ:RGEN) Can Stay On Top Of Its Debt

Jul 15
We Think Repligen (NASDAQ:RGEN) Can Stay On Top Of Its Debt

Repligen: Strong Filtration Growth, Offset By Other Challenges

Jul 13

Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge

Jun 14
Why We're Not Concerned Yet About Repligen Corporation's (NASDAQ:RGEN) 27% Share Price Plunge

Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?

Jun 10
Is Now The Time To Look At Buying Repligen Corporation (NASDAQ:RGEN)?

Repligen Stock: Still Quite Overvalued

May 30

Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

May 03
Repligen Corporation Just Missed Earnings - But Analysts Have Updated Their Models

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Apr 30
Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

Apr 15
Repligen (NASDAQ:RGEN) Has A Pretty Healthy Balance Sheet

At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?

Feb 13
At US$206, Is Repligen Corporation (NASDAQ:RGEN) Worth Looking At Closely?

Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Jan 08
Estimating The Intrinsic Value Of Repligen Corporation (NASDAQ:RGEN)

Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price

Dec 19
Why We're Not Concerned About Repligen Corporation's (NASDAQ:RGEN) Share Price

What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?

Nov 01
What Does Repligen Corporation's (NASDAQ:RGEN) Share Price Indicate?

Is Repligen (NASDAQ:RGEN) Using Too Much Debt?

Oct 17
Is Repligen (NASDAQ:RGEN) Using Too Much Debt?

Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?

Sep 29
Is There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 22% Undervaluation?

Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade

Aug 09
Things Look Grim For Repligen Corporation (NASDAQ:RGEN) After Today's Downgrade

Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?

Jul 17
Does Repligen (NASDAQ:RGEN) Have A Healthy Balance Sheet?

Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?

Jul 03
Is There Now An Opportunity In Repligen Corporation (NASDAQ:RGEN)?

With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case

Jun 19
With EPS Growth And More, Repligen (NASDAQ:RGEN) Makes An Interesting Case

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Olivier Loeillot im Vergleich zu den Einnahmen von Repligen verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Sep 30 2024n/an/a

-US$8m

Jun 30 2024n/an/a

US$9m

Mar 31 2024n/an/a

US$24m

Dec 31 2023US$5mUS$138k

US$36m

Vergütung im Vergleich zum Markt: OlivierDie Gesamtvergütung ($USD5.45M) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD7.94M).

Entschädigung vs. Einkommen: Unzureichende Daten, um die Vergütung von Olivier mit der Unternehmensleistung zu vergleichen.


Geschäftsführer

Olivier Loeillot (54 yo)

1.1yrs

Amtszeit

US$5,445,065

Vergütung

Mr. Olivier Loeillot is President of Repligen Corporation from October 02, 2023 & served as it's Chief Commercial Officer and serves as it's CEO & Director since September 1, 2024. Mr. Loeillot served a co...


Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Anthony Hunt
Executive Chair9.5yrsUS$7.93m0.18%
$ 14.2m
Olivier Loeillot
President1.1yrsUS$5.45mkeine Daten
Jason Garland
CFO & Chief Compliance Officer1.2yrsUS$2.03mkeine Daten
James Bylund
Chief Operating Officer4.7yrsUS$3.74m0.0075%
$ 585.2k
Ralf Kuriyel
Senior Vice President of Research & Development8.1yrsUS$1.66m0.010%
$ 798.4k
Keith Robinson
Chief Information Officerno datakeine Datenkeine Daten
Sondra Newman
Global Head of Investor Relationsno datakeine Datenkeine Daten
Kimberly Cornwell
Global Head of Legalno datakeine Datenkeine Daten
Neil Whitfield
VP & Global Head of Sales2.1yrskeine Datenkeine Daten
Teresa Ferragamo
Senior Director of Marketingless than a yearkeine Datenkeine Daten
Leslie Galvin
Vice President of Human Resources1.8yrskeine Datenkeine Daten
Kola Otitoju
Senior VP of Strategy and Business Development & Global Head of Bioprocess Analytics4.8yrskeine Datenkeine Daten

1.8yrs

Durchschnittliche Betriebszugehörigkeit

60yo

Durchschnittliches Alter

Erfahrenes Management: RGENDas Führungsteam des Unternehmens gilt nicht als erfahren ( 1.8 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.


Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Anthony Hunt
Executive Chair9.5yrsUS$7.93m0.18%
$ 14.2m
Olivier Loeillot
Presidentless than a yearUS$5.45mkeine Daten
Glenn Muir
Independent Director9.1yrsUS$322.84k0.022%
$ 1.7m
Charles Leland Cooney
Member of Scientific Advisory Board8.7yrskeine Datenkeine Daten
Martin Madaus
Independent Director1.8yrsUS$453.50k0.0070%
$ 544.7k
Karen Dawes
Lead Independent Director19.2yrsUS$431.12k0.16%
$ 12.6m
J. Love
Member of Scientific Advisory Board8.7yrskeine Datenkeine Daten
Konstantin Konstantinov
Member of Scientific Advisory Board & Independent Director8.7yrsUS$282.84k0.00095%
$ 73.9k
Steven Cramer
Member of Scientific Advisory Board8.7yrskeine Datenkeine Daten
Rohin Mhatre
Independent Director4.7yrsUS$287.84k0.0042%
$ 326.1k
Richard Braatz
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Nicholas Barthelemy
Independent Director10.4yrsUS$307.84k0.0071%
$ 551.0k

8.7yrs

Durchschnittliche Betriebszugehörigkeit

64yo

Durchschnittliches Alter

Erfahrener Vorstand: RGENDie Vorstandsmitglieder gelten als erfahren (8.7 Jahre durchschnittliche Amtszeit).